Levi & Korsinsky Launches Fraud Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders

Core Viewpoint - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws, following allegations of misleading revenue growth claims related to its product ASCENIV [1][2]. Financial Performance - In Q4 2025, ADMA reported net revenue of $363 million for ASCENIV, marking a 51% year-over-year growth [2]. - However, a short report by Culper Research suggests that this growth may be attributed to "classic channel stuffing," raising concerns about the authenticity of the reported figures [2]. - The discrepancy between ADMA's claimed 20% revenue growth and the alleged 3% decline in underlying demand indicates a significant divergence in performance metrics [2]. Market Reaction - Following the release of the short-seller report on March 24, 2026, ADMA's stock experienced a sharp decline, reflecting investor concerns over the company's revenue reporting practices [2].